验证数据展示
经过测试的应用
| Positive IF-P detected in | human liver cancer tissue |
For other applications, we recommend the unconjugated version of this antibody, 12077-1-AP
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
CL647-12077 targets TINAGL1 in IF-P applications and shows reactivity with human, mouse, rat samples.
| 经测试应用 | IF-P Application Description |
| 经测试反应性 | human, mouse, rat |
| 免疫原 | TINAGL1 fusion protein Ag2721 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | tubulointerstitial nephritis antigen-like 1 |
| 别名 | ARG1, GIS5, LCN7, LIECG3, OLRG 2, OLRG2, PSEC0088, TIN Ag related protein, TIN Ag RP, TINAGL, TINAGL1, TINAGRP, UNQ204/PRO230 |
| 计算分子量 | 467 aa, 52 kDa |
| 观测分子量 | 52 kDa |
| GenBank蛋白编号 | BC009048 |
| 基因名称 | TINAGL1 |
| Gene ID (NCBI) | 64129 |
| RRID | AB_2920220 |
| 偶联类型 | CoraLite® Plus 647 Fluorescent Dye |
| 最大激发/发射波长 | 654 nm / 674 nm |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | Q9GZM7 |
| 储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
| 储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
Tinagl1 (tubulointer stitial nephritis antigen-like 1) is a matricellular protein most commonly associated with embryonic development, including the heart and adrenal glands. Low levels of Tinagl1 expression can be dire for craniofacial development and for female fertility. Tinagl1 can bind to EGFR and integrins on TNBC cells using the 4T1 murine model and that by interrupting normal tumor signaling in this way, cancer proliferation and metastasis pathways were downregulated.
实验方案
| Product Specific Protocols | |
|---|---|
| IF protocol for CL Plus 647 TINAGL1 antibody CL647-12077 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |